Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1

HIV Latency in the Humanized BLT Mouse

(2011) M. D. Marsden et al.   JOURNAL OF VIROLOGY

Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2-/-  c-/- Mouse

(2011) S. K. Choudhary et al.   JOURNAL OF VIROLOGY

Generation of HIV Latency in Humanized BLT Mice

(2011) P. W. Denton et al.   JOURNAL OF VIROLOGY

Rilpivirine: a step forward in tailored HIV treatment

(2011) Rik Schrijvers et al.   LANCET

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Antiretroviral therapy in treatment-naïve patients with HIV infection

(2011) Ricardo Camacho et al.   Current Opinion in HIV and AIDS

Highly Active Antiretroviral Therapy Potently Suppresses HIV Infection in Humanized Rag2-/-γc-/- Mice

(2010) Kaori Sango et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance

(2010) Claudia F. Althaus et al.   JOURNAL OF VIROLOGICAL METHODS

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

(2009) Caroline Bazzoli et al.   CLINICAL PHARMACOKINETICS

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/- c-/- Mouse

(2009) S. K. Choudhary et al.   JOURNAL OF VIROLOGY

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen

(2008) Zoe Fox et al.   AIDS

FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/- C-/- mice in vivo

(2008) Q. Jiang et al.   BLOOD

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL